Format

Send to

Choose Destination
Vaccine. 2007 Aug 14;25(33):6164-6. Epub 2007 Jun 26.

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.

Author information

1
Wyeth Vaccines Research, 401 N. Middletown Road, Pearl River, NY 10965, USA.

Abstract

In a Phase 1 study, 15 healthy subjects were randomized to receive a 13-valent pneumococcal conjugate vaccine (PCV13) and 15 to receive a 23-valent pneumococcal polysaccharide vaccine (23vPS). Antibody responses were measured immediately before and approximately one month after vaccination. Serotype-specific antibodies were measured using an enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G (IgG) and an opsonophagocytic assay (OPA) for functional antibodies. PCV13 was as immunogenic or more immunogenic than 23vPS and was well tolerated.

PMID:
17629361
DOI:
10.1016/j.vaccine.2007.06.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center